Are hemoglobin-based oxygen carriers being withheld because of regulatory requirement for equivalence to packed red blood cells?

American Journal of Therapeutics

Volumn 22, Issue 4, 2015, Pages e115-e121

  Mackenzie, Colin F ^a   Pitman, Arkadiy N ^b   Hodgson, R Eric ^c   Sussman, Martin J ^d   Levien, Lewis J ^e   Jahr, Jonathan S ^f   Greenburg, A Gerson ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b OPK Biotech   (United States)

^c INKOSI ALBERT LUTHULI CENTRAL HOSPITAL   (South Africa)

^d Milpark Business School   (South Africa)

^e Centre for Orthognathic Surgery and Implantology   (South Africa)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN GLUTAMER 256; HEMOGLOBIN RAFFIMER; HEMOSPAN; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG; BLOOD SUBSTITUTE;

ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DEATH; ELECTIVE SURGERY; EMERGENCY CARE; ERYTHROCYTE CONCENTRATE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MORTALITY; MYOCARDIAL DISEASE; OXYGEN TRANSPORT; PATIENT SAFETY; PRIORITY JOURNAL; VASOCONSTRICTION;

BLOOD SUBSTITUTES; HEMOGLOBINS; HUMANS;

EID: 84937630435     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000009     Document Type: Article

References (33)

1. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risKof myocardial infarction and death: a meta-Analysis. JAMA. 2008; 299: 2304-2312
2. Bateman C. MetanalysiScritical of blood alternative product challenged. S Afr Med J. 2008; 98: 746-748
3. Mackenzie CF. Haemoglobin-based oxygen carriers: is the benefit worth the risk?. Br J Hosp Med (Lond). 2009; 70: 26-30
4. Schmidt C. Meta-Analysis torpedoes blood substitutes. Nat Biotechnol. 2008; 26: 721-723
5. Levien LJ, Hodgson RE, James MF. Hemoglobin-based blood substitutes and risKof myocardial infarction and death. JAMA. 2008; 300: 1295; author reply1298-1299
6. Shander A, Javidroozi M, Thompson G. Hemoglobinbased blood substitutes and risKof myocardial infarction and death. JAMA. 2008; 300: 1296-1297; author reply 1298-1299
7. Rentko VT, PearcElB, Moon-Massat PF, et al. Hemopure (HBOC-201, hemoglobin Glutamer-250 (bovine)): Preclinical studies. In: Winslow R, ed. Blood Substitutes. Oxford, United Kingdom: Academic Press; 2006: 424-436
8. Stern S, Rice J, Philbin N, et al. Resuscitation with the hemoglobin-based oxygen carrier, HBOC-201, in a swine model of severe uncontrolled hemorrhage and traumatic brain injury. Shock. 2009; 31: 64-79
9. Freilich D, PearcElB, Pitman AN, et al. HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects-extrapolation of potential risk for acute trauma trials. J Trauma. 2009; 66: 365-376
10. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survivaLafter the use of a hemoglobin-based oxygen carrier in 54 patients with life-Threatening anemia. Anesth Analg. 2010; 110: 685-693
11. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin crosslinked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999; 282: 1857-1864
12. Winslow RM. Current status of oxygen carriers ("blood substitutes"): 2006. Vox Sang. 2006; 91: 102-110
13. Moore EE, Moore FA, Fabian TC, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg. 2009; 208: 1-13
14. Greenhalgh T. Papers that summarise other papers (systematic reviews and meta-Analyses). BMJ. 1997; 315: 672-675. Review
15. Berman NG, Parker RA. Meta-Analysis: neither quick noReasy. BMC Med Res Methodol. 2002; 2: 10
16. Egger M, Smith GD, Phillips AN. Meta-Analysis: principles and procedures. BMJ. 1997; 315: 1533-1537
17. Jahr JS, Mackenzie C, PearcElB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma. 2008; 64: 1484-1497
18. Sprung J, Kindscher JD, Wahr JA, et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, singleblinded trial. Anesth Analg. 2002; 94: 799-808
19. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002; 124: 35-42
20. TElintel Hekkert M, Dube GP, RegaRe, et al. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs. Am J Physiol Heart Circ Physiol. 2010; 298: H1103-H1113
21. Fitzgerald MC, Chan JY, Ross AW, et aLa synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma. Med J Aust. 2011; 194: 471-473
22. Meliga E, Vranckx P, RegaRe, et al. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneouScoronary revascularisation. Rationale, protocol design and haemodynamic results. Euro-Intervention. 2008; 4: 99-107
23. Mongan PD, Moon-Massat PF, Rentko V, et al. Regional blood flow after serial normovolemic exchange transfusion with HBOC-201 (Hemopure) in anesthetized swine. J Trauma. 2009; 67: 51-60
24. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobinbased oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention. 2008; 3: 600-609
25. Bucci E, Kwansa H, Koehler RC, et al. Development of zero-link polymers of hemoglobin, which do not extravasate and do not induce pressure increases upon infusion. Artif Cells Blood Substit Immobil Biotechnol. 2007; 35: 11-18
26. Matheson B, Kwansa HE, Bucci E, et al. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol. 2002; 93: 1479-1486
27. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998; 187: 113-120; discussion 120-122
28. Björkholm M, Fagrell B, Przybelski R, et aLa phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimideactivated polyethylene glycol. Haematologica. 2005; 90: 505-515
29. Katz LM, Manning JE, McCurdy S, et al. HBOC-201 improves survival in a swine model of hemorrhagic shocKand liver injury. Resuscitation. 2002; 54: 77-87
30. Manning JE, Katz LM, Brownstein MR, et al. Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group. Shock. 2000; 13: 152-159
31. Sapa. MCC approveScattle blood meds. The Times Live. 2010. Available at: http://www.timeslive.co.za/scitech/.2010/03/25/mcc-Approves-cattle-blood-meds. Accessed July 7, 2011
32. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update tOthe Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011; 91: 944-982. Review
33. Kim HW, Mozzarelli A, Sakai H, et al. Chapter. 29: academia-industry collaboration in blood substitute development-issues, case histories and a proposal. In: Mozzarelli A, Bettati S, eds. Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood. 1st ed. London, England: John Wiley and Sons Ltd; 2011: 413-428